Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorna Rodriguez-Rodriguez

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Biomarkers in Cancer|March 22, 2016
Role of Biomarkers in the Development of PARP InhibitorsBratati Ganguly, Sonia C Dolfi, Lorna Rodriguez-Rodriguez, et al.
Nanomedicine (London, England)|February 21, 2012
Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastasesMin Zhang, Olga B Garbuzenko, Kenneth R Reuhl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2016
Racial/Ethnic Disparities in Ovarian Cancer Treatment and SurvivalElisa V Bandera, Valerie S Lee, Lorna Rodriguez-Rodriguez, et al.
Investigational New Drugs|November 27, 2002
Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group studyAgustin A Garcia, Michael A Bookman, Lorna Rodriguez-Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2013
Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drugVatsal Shah, Oleh Taratula, Olga B Garbuzenko, et al.
JAMA Oncology|July 17, 2015
Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass IndexElisa V Bandera, Valerie S Lee, Lorna Rodriguez-Rodriguez, et al.
BMC Women'S Health|September 28, 2011
Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control studyElisa V Bandera, Melony King, Urmila Chandran, et al.
Biomarkers in Cancer|February 27, 2016
Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other CancersBhavna S Paratala, Sonia C Dolfi, Hossein Khiabanian, et al.
American Journal of Cancer Research|January 8, 2024
Increased expression of collagen prolyl hydroxylases in ovarian cancer is associated with cancer growth and metastasisMihae Song, Erica Schnettler, Annapoorna Venkatachalam, et al.
Frontiers in Oncology|December 18, 2020
CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3Antons Martincuks, Pei-Chuan Li, Qianqian Zhao, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Biomarkers in Cancer|March 22, 2016
Role of Biomarkers in the Development of PARP InhibitorsBratati Ganguly, Sonia C Dolfi, Lorna Rodriguez-Rodriguez, et al.
Nanomedicine (London, England)|February 21, 2012
Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastasesMin Zhang, Olga B Garbuzenko, Kenneth R Reuhl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2016
Racial/Ethnic Disparities in Ovarian Cancer Treatment and SurvivalElisa V Bandera, Valerie S Lee, Lorna Rodriguez-Rodriguez, et al.
Investigational New Drugs|November 27, 2002
Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group studyAgustin A Garcia, Michael A Bookman, Lorna Rodriguez-Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2013
Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drugVatsal Shah, Oleh Taratula, Olga B Garbuzenko, et al.
JAMA Oncology|July 17, 2015
Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass IndexElisa V Bandera, Valerie S Lee, Lorna Rodriguez-Rodriguez, et al.
BMC Women'S Health|September 28, 2011
Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control studyElisa V Bandera, Melony King, Urmila Chandran, et al.
Biomarkers in Cancer|February 27, 2016
Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other CancersBhavna S Paratala, Sonia C Dolfi, Hossein Khiabanian, et al.
American Journal of Cancer Research|January 8, 2024
Increased expression of collagen prolyl hydroxylases in ovarian cancer is associated with cancer growth and metastasisMihae Song, Erica Schnettler, Annapoorna Venkatachalam, et al.
Frontiers in Oncology|December 18, 2020
CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3Antons Martincuks, Pei-Chuan Li, Qianqian Zhao, et al.
Pageof 7